LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment MT
National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma CI
Peptidream Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024 CI
Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold MT
Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis CI
PeptiDream Inc. Announces Expansion of Peptide Discovery Collaboration with Novartis Pharma AG CI
Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024. CI
Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024. CI
Certain Common Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024. CI
PeptiDream to Partake in Bristol Myers' Tender Offer for All RayzeBio Shares MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024 CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jefferies Adjusts PeptiDream's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Hold MT
Linqmed Inc. announced that it has received ¥680 million in funding from a group of investors CI
PeptiDream Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,300 Yen From 1,600 Yen MT
PeptiDream and Bristol-Myers Squibb to Explore Alternatives as PDL1 Program Faces Setback MT
Peptidream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb Company CI
Jefferies Upgrades PeptiDream to Buy From Hold, Adjusts Price Target to 1,600 Yen From 1,900 Yen MT
PeptiDream Inc. Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide- Radioisotope Drug Conjugates CI
RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million. CI
PeptiDream Unit Pays 4 Billion Yen Contingent Consideration for AMYViD Indication Change; Shares Down 3% MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 CI
PeptiDream Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Astellas Pharma Inc. and PeptiDream Inc. Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders CI
Chart PeptiDream Inc.
More charts
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2,895 JPY
Average target price
3,117 JPY
Spread / Average Target
+7.66%
Consensus
  1. Stock Market
  2. Equities
  3. 4587 Stock
  4. News PeptiDream Inc.
  5. PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment